Triage accuracy of a six-gene methylation detection for high-risk HPV-positive Chinese women

Yue Li, Hongyun Wang, Jun Yang, Huiyan Wang, Jiujun Peng, Ying Hong

Abstract

This study aimed to evaluate the triage accuracy of a six-gene methylation detection test in high-risk human papillomavirus-positive women in China. A total of 369 cervical exfoliated cell samples were collected from high-risk human papillomavirus-positive women undergoing cervical cancer screening at Nanjing Drum Tower Hospital from October 2018 to August 2019. The methylation status of six gene was assessed using real-time methylation-specific polymerase chain reaction. The triage accuracy for cervical intraepithelial neoplasia grade 2 and 3 was compared with that of a commercial methylation kit, cervical cytology, and human papillomavirus types 16/18 tests using receiver operating characteristic curves. Additionally, the effectiveness of the six-gene test for triaging cervical intraepithelial neoplasia grade 2+ and 3+ was validated in 215 samples collected between January and November 2020 and compared with p16/Ki-67 dual-staining cytology. The results demonstrated a significant increase in the positive methylation rate with the severity of cervical intraepithelial neoplasia (P<0.001). This six-gene methylation pattern holds promise for improving triage accuracy in cervical cancer screening for high-risk human papillomavirus-positive women

Full Text:

PDF

References

Wang SM and Qiao YL: Implementation of cervical cancer

screening and prevention in China--challenges and

reality. Jpn J Clin Oncol 2015, 45:7-11.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram

I, Jemal A and Bray F: Global Cancer Statistics 2020:

GLOBOCAN Estimates of Incidence and Mortality

Worldwide for 36 Cancers in 185 Countries. CA

Cancer J Clin 2021, 71:209-249.

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F,

Jemal A, Yu XQ and He J: Cancer statistics in China,

CA Cancer J Clin 2016, 66:115-132.

Lu Y, Li P, Luo G, Liu D and Zou H: Cancer attributable to

human papillomavirus infection in China: Burden

and trends. Cancer 2020, 126:3719-3732.

Zhu B, Liu Y, Zuo T, Cui X, Li M, Zhang J, Yu H and Piao

H: The prevalence, trends, and geographical

distribution of human papillomavirus infection in

China: The pooled analysis of 1.7 million women.

Cancer Med 2019, 8:5373-5385.

zur Hausen H: Papillomaviruses and cancer: from basic

studies to clinical application. Nat Rev Cancer 2002,

:342-350.

Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D and

Smith JS: Persistent human papillomavirus infection

and cervical neoplasia: a systematic review and

meta-analysis. Am J Epidemiol 2008, 168:123-137.

McGraw SL and Ferrante JM: Update on prevention and

screening of cervical cancer. World J Clin Oncol

, 5:744-752.

Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers

CR, Herzig A, Guerra CE, Oeffinger KC, Shih YT,

Walter LC, Brawley OW, Caplan LS, Clark MA,

Cokkinides VE, D'Agostino RB Jr, DeSantis CE,

Ford LG, Freedman AN, Hager BW, Hall IJ, Hing E,

Hong S, Hockenberry M, Ingram D, Jemal A,

Kemeny M, Mandelblatt JS, Mariotto AB, Matthews

AK, McCarter S, McDonald R, Milne RJ, Myers RE,

O'Keefe S, Parmigiani G, Radecki Breitkopf C, Ruhl

J, Samet JM, Sanzari J, Simes J, Simon MS, Sinkins

D, Stewart R, Taylor V, Thompson TD, Tsang G and

Winawer S.: Cervical cancer screening for

individuals at average risk: 2020 guideline update

from the American Cancer Society. CA Cancer J

Clin 2020, 70:321-346.

Zhang M, Zhong Y, Wang L, Bao H, Huang Z, Zhao Z,

Zhang X, Li C, Sun KL, Wu J, Li X, Liu Y, Liu X,

Li Z, Wang H, Wei J, Li J, Zhang J, Yang Y, Gao L,

Wang J, Guo X, Xu Y, Ma H, Li Y and Wang Y.:

Cervical Cancer Screening Coverage - China, 2018

China CDC Wkly 2022, 4:1077-1082.

Perkins RB, Wentzensen N and Schiffman M: Primary

HPV Screening vs Cotesting for Cervical Cancer

Reply. Jama 2023, 330:2121-2122.

Ebisch RM, Siebers AG, Bosgraaf RP, Massuger LF,

Bekkers RL and Melchers WJ: Triage of high-risk

HPV positive women in cervical cancer screening.

Expert Rev Anticancer Ther 2016, 16:1073-1085.

Hillyar CR, Kanabar SS, Pufal KR, Lawson AW, Saw Hee

JL, Rallis KS, Nibber A and Sideris M: A systematic

review and meta-analysis of the diagnostic

effectiveness of human papillomavirus methylation

biomarkers for detection of cervical cancer.

Epigenomics 2022, 14:1055-1072.

Spencer JC and Wheeler CM: Promise and Perils of

Primary HPV Testing. Cancer Epidemiol

Biomarkers Prev 2024, 33:982-983.

Jiao X, Zhang S, Jiao J, Zhang T, Qu W, Muloye GM, Kong

B, Zhang Q and Cui B: Promoter methylation of

SEPT9 as a potential biomarker for early detection of

cervical cancer and its overexpression predicts

radioresistance. Clin Epigenetics 2019, 11:120.

Castle PE, Adcock R, Cuzick J, Wentzensen N, Torrez

Martinez NE, Torres SM, Stoler MH, Ronnett BM,

Joste NE, Darragh TM, Huh WK, Garcia FA,

Hesselink AT and Schiffman M.: Relationships of

p16 Immunohistochemistry and Other Biomarkers

With Diagnoses of Cervical Abnormalities:

Implications for LAST Terminology. Arch Pathol

Lab Med 2020, 144:725-734.

Wright TC, Jr., Stoler MH, Ranger-Moore J, Fang Q,

Volkir P, Safaeian M and Ridder R: Clinical

validation of p16/Ki-67 dual-stained cytology triage

of HPV-positive women: Results from the IMPACT

trial. Int J Cancer 2022, 150:461-471.

Mao Z, Wang B, Zhang T and Cui B: The roles of m6A

methylation in cervical cancer: functions, molecular

mechanisms, and clinical applications. Cell Death

Dis 2023, 14:734.

Wang Y, Chuan J, Zhu B, Zu Y, Zhang R, Tang L, Wen Y,

Yang T, Chen K, Chen X, Liu Y, Wang J, Zhao X,

Xu Z, Yang L and Zhang S.: Evaluation of

PAX1/ST6GALNAC5 methylation as a triage test

for cervical intraepithelial neoplasia and cervical

cancer. Epigenomics 2023, 15:131-145.

Bowden SJ, Ellis LB, Kalliala I, Paraskevaidi M, Tighe J,

Kechagias KS, Doulgeraki T, Paraskevaidis E, Arbyn M, Flanagan J, Martin-Hirsch PL, Murray G,

Ordi J, Romero I, Ryan M, Snijders PJF, Wentzensen

N, Loughlin L, de Sanjose S and Dasari S.: Protocol

for a systematic review and meta-analysis of the

diagnostic test accuracy of host and HPV DNA

methylation in cervical cancer screening and

management. BMJ Open 2023, 13:e071534.

Cao D, Yang Z, Dong S, Li Y, Mao Z, Lu Q, Xu P, Shao

M, Pan L, Han X, Li J, Zhang Y, Wang X, Zhao L,

Zhou L, Yang Y and Li Z.: PCDHGB7

hypermethylation-based

Cervical

cancer

Methylation (CerMe) detection for the triage of high

risk human papillomavirus-positive women: a

prospective cohort study. BMC Med 2024, 22:55.

Hansel A, Steinbach D, Greinke C, Schmitz M, Eiselt J,

Scheungraber C, Gajda M, Hoyer H, Runnebaum IB

and Dürst M: A promising DNA methylation

signature for the triage of high-risk human

papillomavirus DNA-positive women. PLoS One

, 9:e91905.

Schmitz M, Eichelkraut K, Schmidt D, Zeiser I, Hilal Z,

Tettenborn Z, Hansel A and Ikenberg H:

Performance of a DNA methylation marker panel

using liquid-based cervical scrapes to detect cervical

cancer and its precancerous stages. BMC Cancer

, 18:1197.

Shu R, He J, Wu C and Gao J: The association between

RARβ and FHIT promoter methylation and the

carcinogenesis of patients with cervical carcinoma:

A meta-analysis.

Tumour

:1010428317709126.

Biol

,

Naseem A, Bhat ZI, Kalaiarasan P, Kumar B, Gandhi G,

Rizvi MMA: Genetic and epigenetic alterations

affecting PARK-2 expression in cervical neoplasm

among North Indian patients. Tumour Biol 2017,

:1010428317703635.

Niyazi M, Sui S, Zhu K, Wang L, Jiao Z and Lu P:

Correlation between Methylation of Human

Papillomavirus-16 L1 Gene and Cervical Carcinoma

in Uyghur Women. Gynecol Obstet Invest 2017,

:22-29.

Zhang J, Zhao Y, Dai Y, Dang L, Ma L, Yang C, Li Y,

Kong L, Wei L, Zhang S, Xie L, Li Y, Chen Q, Li X,

Lu J, Xie X, Liang Z, Liang X, Wang Q, Yang J,

Zhang X, Wang J, Zhan Z and Wang T.:

Effectiveness of High-risk Human Papillomavirus

Testing for Cervical Cancer Screening in China: A

Multicenter, Open-label, Randomized Clinical Trial.

JAMA Oncol 2021, 7:263-270.

Zhao Y, Bao H, Ma L, Song B, Di J, Wang L, Gao Y, Ren

W, Wang S, Wang HJ and Wu J: Real-world

effectiveness of primary screening with high-risk

human papillomavirus testing in the cervical cancer

screening programme in China: a nationwide,

population-based study. BMC Med 2021, 19:164.

Shi L, Yang X, He L, Zheng C, Ren Z, Warsame JA, Suye

S, Yan L, Cai H, Xiao X and Fu C: Promoter

hypermethylation analysis of host genes in cervical

intraepithelial neoplasia and cervical cancers on

histological cervical specimens. BMC Cancer 2023,

:168.

Tu J, Chen S, Wu S, Wu T, Fan R and Kuang Z: Tumor

DNA Methylation Profiles Enable Diagnosis,

Prognosis Prediction, and Screening for Cervical

Cancer. Int J Gen Med 2022, 15:5809-5821.

Schreiberhuber L, Barrett JE, Wang J, Redl E, Herzog C,

Vavourakis CD, Sundström K, Dillner J and

Widschwendter M: Cervical cancer screening using

DNA methylation triage in a real-world population.

Nat Med 2024, 30:2251-2257.

Liang LA, Einzmann T, Franzen A, Schwarzer K,

Schauberger G, Schriefer D, Radde K, Zeissig SR,

Ikenberg H, Meijer C, Dijkstra MG, van der Graaf Y,

van Kemenade FJ, Dillner J, von Krogh G, Kalliala I

and Arbyn M.: Cervical Cancer Screening:

Comparison of Conventional Pap Smear Test,

Liquid-Based Cytology, and Human Papillomavirus

Testing as Stand-alone or Cotesting Strategies.

Cancer Epidemiol Biomarkers Prev 2021, 30:474

Simms KT, Keane A, Nguyen DTN, Caruana M, Hall MT,

Lui G, Gauvreau C, Demke O, Arbyn M, Basu P, Paltiel

AD, Fennell S, Marnitz S, McBride A, Miller J and Tsu

V: Benefits, harms and cost-effectiveness of cervical

screening, triage and treatment strategies for women in

the general population. Nat Med 2023, 29:3050-3058.

Spence AR, Goggin P and Franco EL: Process of care

failures in invasive cervical cancer: systematic

review and meta-analysis. Prev Med 2007, 45:93

Bhatla N and Singhal S: Primary HPV screening for

cervical cancer. Best Pract Res Clin Obstet Gynaecol

, 65:98-108.

Perkins RB, Wentzensen N, Guido RS, Schiffman M:

Cervical Cancer Screening: A Review. Jama 2023,

:547-558.

Thomsen LT, Kjaer SK, Munk C, Ørnskov D and

Waldstrøm M: Benefits and potential harms of

human papillomavirus (HPV)-based cervical cancer

screening: A real-world comparison of HPV testing

versus cytology. Acta Obstet Gynecol Scand 2021,

:394-402.

Ebisch RM, van der Horst J, Hermsen M, Rijstenberg LL,

Vedder JE, Bulten J, Bosgraaf RP, Verhoef VM,

Heideman DA, Snijders PJ, Meijer CJ, de Wilde L,

Quint W and van Kemenade FJ.: Evaluation of

p16/Ki-67 dual-stained cytology as triage test for

high-risk human papillomavirus-positive women.

Mod Pathol 2017, 30:1021-1031.

Clarke MA, Cheung LC, Castle PE, Schiffman M,

Tokugawa D, Poitras N, Lorey T, Kinney W and

Wentzensen N: Five-Year Risk of Cervical Precancer

Following p16/Ki-67 Dual-Stain Triage of HPV

Positive Women. JAMA Oncol 2019, 5:181-186

Refbacks

  • There are currently no refbacks.